Detalhe da pesquisa
1.
A community challenge to predict clinical outcomes after immune checkpoint blockade in non-small cell lung cancer.
J Transl Med
; 22(1): 190, 2024 Feb 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-38383458
2.
Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer.
N Engl J Med
; 381(21): 2020-2031, 2019 11 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-31562796
3.
Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden.
N Engl J Med
; 378(22): 2093-2104, 2018 May 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-29658845
4.
First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer.
N Engl J Med
; 376(25): 2415-2426, 2017 06 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-28636851
5.
Bempegaldesleukin plus nivolumab in untreated, unresectable or metastatic melanoma: Phase III PIVOT IO 001 study design.
Future Oncol
; 16(28): 2165-2175, 2020 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-32723187
6.
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck.
N Engl J Med
; 375(19): 1856-1867, 2016 11 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-27718784
7.
Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study.
Lancet Oncol
; 18(1): 31-41, 2017 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27932067
8.
Clinical Benefit From Immunotherapy in Patients With SCLC Is Associated With Tumor Capacity for Antigen Presentation.
J Thorac Oncol
; 18(9): 1222-1232, 2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37210008
9.
Bioinformatic Methods and Bridging of Assay Results for Reliable Tumor Mutational Burden Assessment in Non-Small-Cell Lung Cancer.
Mol Diagn Ther
; 23(4): 507-520, 2019 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-31250328
10.
First-Line Nivolumab Plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers.
J Clin Oncol
; 37(12): 992-1000, 2019 04 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-30785829
11.
Five-Year Follow-Up of Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer: Results From the CA209-003 Study.
J Clin Oncol
; 36(17): 1675-1684, 2018 06 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-29570421
12.
Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer.
Cancer Cell
; 33(5): 853-861.e4, 2018 05 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-29731394
13.
Nivolumab Plus Erlotinib in Patients With EGFR-Mutant Advanced NSCLC.
J Thorac Oncol
; 13(9): 1363-1372, 2018 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-29802888
14.
Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer.
Cancer Cell
; 33(5): 843-852.e4, 2018 05 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-29657128
15.
Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057).
J Clin Oncol
; 35(35): 3924-3933, 2017 Dec 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-29023213
16.
Implementation of Amplicon Parallel Sequencing Leads to Improvement of Diagnosis and Therapy of Lung Cancer Patients.
J Thorac Oncol
; 10(7): 1049-57, 2015 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-26102443
17.
Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer.
Cancer Cell
; 35(2): 329, 2019 Feb 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-30753829
18.
Dasatinib plus capecitabine for advanced breast cancer: safety and efficacy in phase I study CA180004.
Clin Cancer Res
; 19(7): 1884-93, 2013 Apr 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-23403636
19.
Genetic analysis implicates resistin in HIV lipodystrophy.
AIDS
; 22(13): 1561-8, 2008 Aug 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-18670214
20.
Genetic and gene expression studies implicate renin and endothelin-1 in edema caused by peroxisome proliferator-activated receptor gamma agonists.
Pharmacogenet Genomics
; 18(10): 903-10, 2008 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-18794727